This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
'''Butylone''' (also known as '''β-keto-''N''-methylbenzodioxolylbutanamine''', '''βk-MBDB''', or '''B1''') is a synthetic [[entactogen]] and [[psychoactive class::stimulant]] substance of the [[chemical class::cathinone]] class. It is the β-keto analog of [[MBDB]] and the substituted methylenedioxy analogue of [[buphedrone]].
'''Butylone''' (also known as '''β-keto-''N''-methylbenzodioxolylbutanamine''', '''βk-MBDB''', or '''B1''') is a synthetic [[entactogen]] and [[psychoactive class::stimulant]] substance of the [[chemical class::cathinone]] class. It is the β-keto analog of [[MBDB]] and the substituted methylenedioxy analogue of [[buphedrone]].
As a [[designer drug]], it is commonly sold on the street along with [[ethylone]] as a substitute or counterfeit for [[MDMA]] and [[methylone]] (all of which have collectively come to be referred to as "Molly") due to methylone's declining availability on the [[research chemical]] market. However, in spite of behavioral and pharmacological similarities between butylone and MDMA, the observed subjective effects of both substances are not completely identical. <ref name="urlCathinone | Ask Dr. Shulgin Online">{{cite web | url = http://www.cognitiveliberty.org/shulgin/adsarchive/cathinone.htm | title = Cathinone | Ask Dr. Shulgin Online }}</ref>
As a [[designer drug]], it is commonly sold on the street along with [[ethylone]] as a substitute or counterfeit for [[MDMA]] and [[methylone]] (all of which have collectively come to be referred to as "Molly") due to methylone's declining availability on the [[research chemical]] market. However, in spite of behavioral and pharmacological similarities between butylone and MDMA, the observed subjective effects of both substances are not completely identical.<ref name="urlCathinone | Ask Dr. Shulgin Online">{{cite web | url = http://www.cognitiveliberty.org/shulgin/adsarchive/cathinone.htm | title = Cathinone | Ask Dr. Shulgin Online }}</ref>
Subjective effects include [[stimulation]], [[thought acceleration]], [[motivation enhancement]], [[increased libido]], [[appetite suppression]], and [[euphoria]], Butylone is reported to be less potent than its relatives [[methylone]] and [[ethylone]] as well as possessing more classic [[stimulant]] as opposed to entactogenic effects.
Subjective effects include [[stimulation]], [[thought acceleration]], [[motivation enhancement]], [[increased libido]], [[appetite suppression]], and [[euphoria]], Butylone is reported to be less potent than its relatives [[methylone]] and [[ethylone]] as well as possessing more classic [[stimulant]] as opposed to entactogenic effects.
Line 15:
Line 15:
==Pharmacology==
==Pharmacology==
Butylone acts as a mixed [[reuptake inhibitor]]/[[releasing agent]] of [[serotonin]], [[norepinephrine]], and [[dopamine]].<ref>Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/10528135</ref><ref>The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain (ScienceDirect) | http://www.sciencedirect.com/science/article/pii/S0014299906013811</ref> These are the [[neurotransmitters]] in charge of pleasure, reward, motivation and focus. This is done by inhibiting the reuptake and reabsorption of the neurotransmitters after they have performed their function of transmitting a neural impulse, essentially allowing them to accumulate and be reused, causing physically stimulating and euphoric effects.
Butylone acts as a mixed [[reuptake inhibitor]]/[[releasing agent]] of [[serotonin]], [[norepinephrine]], and [[dopamine]].<ref>{{cite journal | vauthors=((Cozzi, N. V.)), ((Sievert, M. K.)), ((Shulgin, A. T.)), ((Jacob, P.)), ((Ruoho, A. E.)) | journal=European Journal of Pharmacology | title=Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines | volume=381 | issue=1 | pages=63–69 | date=17 September 1999 | issn=0014-2999 | doi=10.1016/s0014-2999(99)00538-5}}</ref><ref name="Nagai2007">{{cite journal | vauthors=((Nagai, F.)), ((Nonaka, R.)), ((Satoh Hisashi Kamimura, K.)) | journal=European Journal of Pharmacology | title=The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain | volume=559 | issue=2 | pages=132–137 | date=22 March 2007 | url=https://www.sciencedirect.com/science/article/pii/S0014299906013811 | issn=0014-2999 | doi=10.1016/j.ejphar.2006.11.075}}</ref> These are the [[neurotransmitters]] in charge of pleasure, reward, motivation and focus. This is done by inhibiting the reuptake and reabsorption of the neurotransmitters after they have performed their function of transmitting a neural impulse, essentially allowing them to accumulate and be reused, causing physically stimulating and euphoric effects.
In comparison to [[methylone]], it has approximately over 4x lower affinity for the norepinephrine transporter, while its affinity for the serotonin and dopamine transporters is similar.<ref>"Pharmacological characterization of designer cathinones in vitro" | http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2012.02145.x/pdf</ref><ref>The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain (ScienceDirect) | http://www.sciencedirect.com/science/article/pii/S0014299906013811</ref> The results of these differences in pharmacology relative to [[MDMA]] is that butylone, like its close analog [[ethylone]] is less potent in terms of dose, has more balanced [[catecholaminergic]] effects relative to serotonergic, and behaves more like a [[reuptake inhibitor]] like [[methylphenidate]] than a releaser like [[amphetamine]]; however, butylone still has relatively robust releasing capabilities.<ref>"Pharmacological characterization of designer cathinones in vitro" | http://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2012.02145.x/pdf</ref>
In comparison to [[methylone]], it has approximately over 4x lower affinity for the norepinephrine transporter, while its affinity for the serotonin and dopamine transporters is similar.<ref name="Simmler2013">{{cite journal | vauthors=((Simmler, L.)), ((Buser, T.)), ((Donzelli, M.)), ((Schramm, Y.)), ((Dieu, L.-H.)), ((Huwyler, J.)), ((Chaboz, S.)), ((Hoener, M.)), ((Liechti, M.)) | journal=British Journal of Pharmacology | title=Pharmacological characterization of designer cathinones in vitro: Pharmacology of cathinones | volume=168 | issue=2 | pages=458–470 | date= January 2013 | url=https://onlinelibrary.wiley.com/doi/10.1111/j.1476-5381.2012.02145.x | issn=00071188 | doi=10.1111/j.1476-5381.2012.02145.x}}</ref><ref name="Nagai2007"/> The results of these differences in pharmacology relative to [[MDMA]] is that butylone, like its close analog [[ethylone]] is less potent in terms of dose, has more balanced [[catecholaminergic]] effects relative to serotonergic, and behaves more like a [[reuptake inhibitor]] like [[methylphenidate]] than a releaser like [[amphetamine]]; however, butylone still has relatively robust releasing capabilities.<ref name="Simmler2013"/>
==Subjective effects==
==Subjective effects==
Line 79:
Line 79:
===Psychosis===
===Psychosis===
{{Main|Stimulant psychosis}}
{{Main|Stimulant psychosis}}
Abuse of compounds within the stimulant class at high dosages for prolonged periods of time can potentially result in a stimulant psychosis that may present with a variety of symptoms (e.g., [[Paranoia|paranoia]], [[External hallucinations|hallucinations]], or [[Delusions|delusions]]).<ref>Treatment for amphetamine psychosis | [http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003026.pub3/abstract?systemMessage=Wiley+Online+Library+will+be+disrupted+Saturday%2C+15+March+from+10%3A00-12%3A00+GMT+%2806%3A00-08%3A00+EDT%29+for+essential+maintenance]</ref> A review on treatment for amphetamine, [[amphetamine|dextroamphetamine]], and [[methamphetamine]] abuse-induced psychosis states that about 5–15% of users fail to recover completely.<ref>Treatment for amphetamine psychosis | [http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003026.pub3/abstract?systemMessage=Wiley+Online+Library+will+be+disrupted+Saturday%2C+15+March+from+10%3A00-12%3A00+GMT+%2806%3A00-08%3A00+EDT%29+for+essential+maintenance]</ref><ref>Hofmann FG (1983). A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects (2nd ed.). New York: Oxford University Press. p. 329. ISBN 9780195030570.</ref> The same review asserts that, based upon at least one trial, [[antipsychotic]] medications effectively resolve the symptoms of acute amphetamine psychosis.<ref>Treatment for amphetamine psychosis | [http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003026.pub3/abstract?systemMessage=Wiley+Online+Library+will+be+disrupted+Saturday%2C+15+March+from+10%3A00-12%3A00+GMT+%2806%3A00-08%3A00+EDT%29+for+essential+maintenance]</ref> Psychosis very rarely arises from therapeutic use.<ref>Stimulant Misuse: Strategies to Manage a Growing Problem | http://www.acha.org/prof_dev/ADHD_docs/ADHD_PDprogram_Article2.pdf</ref><ref>http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf</ref>
Abuse of compounds within the stimulant class at high dosages for prolonged periods of time can potentially result in a stimulant psychosis that may present with a variety of symptoms (e.g., [[Paranoia|paranoia]], [[External hallucinations|hallucinations]], or [[Delusions|delusions]]).<ref name="Shoptaw2009">{{cite journal | vauthors=((Shoptaw, S. J.)), ((Kao, U.)), ((Ling, W.)) | veditors=((Cochrane Drugs and Alcohol Group)) | journal=Cochrane Database of Systematic Reviews | title=Treatment for amphetamine psychosis | date=21 January 2009 | url=https://doi.wiley.com/10.1002/14651858.CD003026.pub3 | issn=14651858 | doi=10.1002/14651858.CD003026.pub3}}</ref> A review on treatment for amphetamine, [[amphetamine|dextroamphetamine]], and [[methamphetamine]] abuse-induced psychosis states that about 5–15% of users fail to recover completely.<ref name="Shoptaw2009"/><ref>{{cite book | vauthors=((Hofmann, F. G.)) | date= 1983 | title=A handbook on drug and alcohol abuse: the biomedical aspects | publisher=Oxford University Press | edition=2nd ed | isbn=9780195030563}}</ref> The same review asserts that, based upon at least one trial, [[antipsychotic]] medications effectively resolve the symptoms of acute amphetamine psychosis.<ref name="Shoptaw2009"/> Psychosis very rarely arises from therapeutic use.<ref>http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf</ref>
===Dangerous interactions===
===Dangerous interactions===
{{DangerousInteractions/Intro}}
{{DangerousInteractions/Intro}}
Line 94:
Line 94:
*'''China''': As of October 2015 butylone is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref>
*'''China''': As of October 2015 butylone is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref>
*'''Finland''': Butylone is a controlled substance.{{citation needed}}
*'''Finland''': Butylone is a controlled substance.{{citation needed}}
*'''France''': Butylone is scheduled as a "stupéfiant", i.e. a recognized drug of abuse. It is illegal to possess, buy, sell or manufacture.<ref>{{Citation | title=Arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants | url=https://www.legifrance.gouv.fr/loda/id/JORFTEXT000000533085/2020-11-20/}}</ref>
*'''Germany''': Butylone is controlled under Anlage II BtMG (''Narcotics Act, Schedule II'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html|title=Anlage II BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 25, 2019|language=de}}</ref> as of July 26, 2012.<ref>{{cite web|url=https://www.bgbl.de/xaver/bgbl/start.xav?start=%2F%2F*%5B%40attr_id%3D%27bgbl112s1639.pdf%27%5D|title=Sechsundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften|publisher=Bundesanzeiger Verlag|access-date=December 25, 2019|language=de}}</ref> It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/__29.html|title=§ 29 BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 25, 2019|language=de}}</ref>
*'''Germany''': Butylone is controlled under Anlage II BtMG (''Narcotics Act, Schedule II'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html|title=Anlage II BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 25, 2019|language=de}}</ref> as of July 26, 2012.<ref>{{cite web|url=https://www.bgbl.de/xaver/bgbl/start.xav?start=%2F%2F*%5B%40attr_id%3D%27bgbl112s1639.pdf%27%5D|title=Sechsundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften|publisher=Bundesanzeiger Verlag|access-date=December 25, 2019|language=de}}</ref> It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/__29.html|title=§ 29 BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 25, 2019|language=de}}</ref>
*'''Israel''': Butylone is a controlled substance.{{citation needed}}
*'''Israel''': Butylone is a controlled substance.{{citation needed}}
Line 101:
Line 102:
*'''Sweden''': Butylone is a Schedule I controlled substance as of February 1, 2010.<ref>{{cite web|url=https://lakemedelsverket.se/upload/lvfs/LVFS_2010-1.pdf | title=Föreskrifter om ändring i Läkemedelsverkets föreskrifter (LVFS 1997:12) om förteckningar över narkotika| publisher=Läkemedelsverkets författningssamling|language=Swedish|access-date=December 25, 2019}}</ref>
*'''Sweden''': Butylone is a Schedule I controlled substance as of February 1, 2010.<ref>{{cite web|url=https://lakemedelsverket.se/upload/lvfs/LVFS_2010-1.pdf | title=Föreskrifter om ändring i Läkemedelsverkets föreskrifter (LVFS 1997:12) om förteckningar över narkotika| publisher=Läkemedelsverkets författningssamling|language=Swedish|access-date=December 25, 2019}}</ref>
*'''Switzerland''': Butylone is a controlled substance specifically named under Verzeichnis D.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''Switzerland''': Butylone is a controlled substance specifically named under Verzeichnis D.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''United Kingdom''': Butylone is a Class B drug in the United Kingdom as a result of the cathinone catch-all clause.<ref>United Kingdom. (2010). Misuse of Drugs Act 1971 (S.I. 2010/1207). London: The Stationery Office Limited. Retrieved February 9, 2018, from https://www.legislation.gov.uk/uksi/2010/1207/made</ref>
*'''United Kingdom''': Butylone is a Class B drug in the United Kingdom as a result of the cathinone catch-all clause.<ref>{{Citation | title=The Misuse of Drugs Act 1971 (Amendment) Order 2010 | url=https://www.legislation.gov.uk/uksi/2010/1207/made}}</ref>
*'''United States''': Butylone is unscheduled in the United States. However it could be considered an analog of [[methylone]] or [[MDMA]], thus making it illegal under the scope of the Federal Analog Act.{{citation needed}}
*'''United States''': Butylone is unscheduled in the United States. However it could be considered an analog of [[methylone]] or [[MDMA]], thus making it illegal under the scope of the Federal Analog Act.{{citation needed}}
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.
DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
Butylone (also known as β-keto-N-methylbenzodioxolylbutanamine, βk-MBDB, or B1) is a synthetic entactogen and stimulant substance of the cathinone class. It is the β-keto analog of MBDB and the substituted methylenedioxy analogue of buphedrone.
As a designer drug, it is commonly sold on the street along with ethylone as a substitute or counterfeit for MDMA and methylone (all of which have collectively come to be referred to as "Molly") due to methylone's declining availability on the research chemical market. However, in spite of behavioral and pharmacological similarities between butylone and MDMA, the observed subjective effects of both substances are not completely identical._Ask_Dr._Shulgin_Online-1|[1]
Butylone has a very short history of human use and very little data exists about its pharmacological properties, metabolism, and toxicity. It is highly advised to use harm reduction practices if using this substance.
Butylone, or β-keto-N-methylbenzodioxolylbutanamine, is a synthetic molecule of the cathinone family. Cathinones are structurally similar to amphetamines in that they contain a phenethylamine core featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain with an additional ethyl substitution at Rα. Cathinones such as butylone are alpha-methylated phenethylamines (i.e. amphetamines) but differ from them with the addition of a ketone functional group (a carbonyl group at Rβ). Butylone contains a methyl substitution at RN, a substitution which is shared with MDEA, ethylone, 4-MEC, and certain other stimulants and entactogens. Additionally, butylone contains substitutions at R3 and R4 of the phenyl ring with oxygen groups. These oxygen groups are incorporated into a methylenedioxy ring through a methylene chain. Butylone shares this methylenedioxy ring with MDA, MDAI and MDMA.
Pharmacology
Butylone acts as a mixed reuptake inhibitor/releasing agent of serotonin, norepinephrine, and dopamine.[2][3] These are the neurotransmitters in charge of pleasure, reward, motivation and focus. This is done by inhibiting the reuptake and reabsorption of the neurotransmitters after they have performed their function of transmitting a neural impulse, essentially allowing them to accumulate and be reused, causing physically stimulating and euphoric effects.
In comparison to methylone, it has approximately over 4x lower affinity for the norepinephrine transporter, while its affinity for the serotonin and dopamine transporters is similar.[4][3] The results of these differences in pharmacology relative to MDMA is that butylone, like its close analog ethylone is less potent in terms of dose, has more balanced catecholaminergic effects relative to serotonergic, and behaves more like a reuptake inhibitor like methylphenidate than a releaser like amphetamine; however, butylone still has relatively robust releasing capabilities.[4]
Subjective effects
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWikicontributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
Physical effects
Stimulation - In terms of its effects on the user's physical energy levels, butylone is commonly considered to be highly stimulating and energetic. This encourages activities such as running, climbing and dancing in a way that makes butylone a popular choice for musical events such as festivals and raves. The particular style of stimulation which butylone presents can be described as forced. This means that at higher doses, it becomes difficult or impossible to keep still as jaw clenching, involuntarily bodily shakes, and vibrations become present, resulting in an extreme unsteadiness of the hands and a general lack of motor control.
Spontaneous physical sensations - The "body high" of butylone can be described as a strong euphoric tingling sensation that encompasses the entire body. It is capable of becoming overwhelmingly pleasurable at higher doses. This sensation maintains a consistent presence that steadily rises with the onset and hits its limit once the peak has been reached.
Vibrating vision - At high doses, a person's eyeballs may begin to spontaneously wiggle back and forth in a rapid motion, causing the vision to become blurry and temporarily out of focus. This is a condition known as nystagmus.
Dehydration - Feelings of dry mouth and dehydration are a universal experience with butylone; this effect is a product of an increased heart rate and an extreme motivation to engage in strenuous physical activities. While it is important to avoid becoming dehydrated (especially when out dancing in a hot environment) there have been some users suffering from water intoxication through over-drinking, so it is advised that users simply sip at water and never over-drink.
Difficulty urinating - Higher doses of butylone result in an overall difficulty when it comes to urination. This is an effect that is entirely temporary and harmless. It is due to butylone’s promotion of the release of anti-diuretic hormone (ADH). ADH is responsible for regulating urination. This effect can be lessened by simply relaxing, but can be significantly relieved by placing a hot flannel over the genitals to warm them up and encourage blood flow.
Teeth grinding - This component can be considered to be less intense when compared with that of MDMA.
Cognitive effects
The cognitive effects of butylone can be broken down into several components which progressively intensify proportional to dosage. The general headspace of butylone is described by many as one of extreme mental stimulation, light feelings of love or empathy and moderate euphoria. It contains a large number of typical psychedelic, entactogenic and stimulant cognitive effects.
The most prominent of these cognitive effects include:
Cognitive euphoria - Strong emotional euphoria and feelings of happiness are present within butylone and are likely a direct result of serotonin and dopamine release. In comparison to MDMA, it is closer in effects to that of the euphoria felt within amphetamine and mephedrone.
Empathy, love, and sociability enhancement - Although distinct and powerful in its effects, this particular feeling is less pronounced and therapeutic when compared to that of MDMA. It can be described as less forceful and more internal in its manifestation, resulting in feelings of love and empathy that are not necessarily felt as essential to express to others.
Time distortion - Strong feelings of time compression are common within butylone and speed up the experience of time quite noticeably.
The effects which occur during the offset of a stimulant experience generally feel negative and uncomfortable in comparison to the effects which occurred during its peak. This is often referred to as a "comedown" and occurs because of neurotransmitter depletion. Its effects commonly include:
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
The toxicity and long-term health effects of recreational butylone use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because butylone has very little history of human usage. Anecdotal evidence from people who have tried butylone within the community suggests that there do not seem to be strong adverse effects attributed to using this substance at low to moderate doses and sparingly.
As with other stimulants, the chronic use of butylone can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.
Tolerance to many of the effects of butylone develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). Butylone presents cross-tolerance with [[Cross-tolerance::all dopaminergicstimulants]], meaning that after the consumption of butylone all stimulants will have a reduced effect.
Abuse of compounds within the stimulant class at high dosages for prolonged periods of time can potentially result in a stimulant psychosis that may present with a variety of symptoms (e.g., paranoia, hallucinations, or delusions).[5] A review on treatment for amphetamine, dextroamphetamine, and methamphetamine abuse-induced psychosis states that about 5–15% of users fail to recover completely.[5][6] The same review asserts that, based upon at least one trial, antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis.[5] Psychosis very rarely arises from therapeutic use.[7]
Dangerous interactions
Warning:Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
"[[DangerousInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] & "[[DangerousInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - 25x compounds are highly stimulating and physically straining. Combinations with Butylone should be strictly avoided due to the risk of excessive stimulation and heart strain. This can result in increased blood pressure, vasoconstriction, panic attacks, thought loops, seizures, and heart failure in extreme cases.
"[[UncertainInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Combining alcohol with stimulants can be dangerous due to the risk of accidental over-intoxication. Stimulants mask alcohol's depressant effects, which is what most people use to assess their degree of intoxication. Once the stimulant wears off, the depressant effects will be left unopposed, which can result in blackouts and severe respiratory depression. If mixing, the user should strictly limit themselves to only drinking a certain amount of alcohol per hour.
"[[UnsafeInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Combinations with DXM should be avoided due to its inhibiting effects on serotonin and norepinephrine reuptake. There is an increased risk of panic attacks and hypertensive crisis, or serotonin syndrome with serotonin releasers (MDMA, methylone, mephedrone, etc.). Monitor blood pressure carefully and avoid strenuous physical activity.
"[[UnsafeInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Any neurotoxic effects of MDMA are likely to be increased when other stimulants are present. There is also a risk of excessive blood pressure and heart strain (cardiotoxicity).
"[[UncertainInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Some reports suggest combinations with MXE may dangerously increase blood pressure and increase the risk of mania and psychosis.
"[[UncertainInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Both classes carry a risk of delusions, mania and psychosis, and these risk may be multiplied when combined.
"[[UnsafeInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Butylone may be dangerous to combine with other stimulants like cocaine as they can increase one's heart rate and blood pressure to dangerous levels.
"[[DangerousInteraction" contains a listed "[" character as part of the property label and has therefore been classified as invalid.]] - Tramadol is known to lower the seizure threshold[8] and combinations with stimulants may further increase this risk.
Combinations with the following substances can cause dangerously high serotonin levels. Serotonin syndrome requires immediate medical attention and can be fatal if left untreated.
As such, it may contain incomplete or wrong information. You can help by expanding it.
Austria: Butylone is illegal to possess, produce and sell under the NPSG (New Psychoactive Substances Act).[citation needed]
Brazil: As of September 7, 2018, all cathinone analogues are controlled substances considered illegal to possess, use and distribute. This was made possible due to a blanket ban law appended to Portaria SVS/MS nº 344.[10]
Canada: Butylone is controlled as a Schedule I substance.[citation needed]
China: As of October 2015 butylone is a controlled substance in China.[11]
Finland: Butylone is a controlled substance.[citation needed]
France: Butylone is scheduled as a "stupéfiant", i.e. a recognized drug of abuse. It is illegal to possess, buy, sell or manufacture.[12]
Germany: Butylone is controlled under Anlage II BtMG (Narcotics Act, Schedule II)[13] as of July 26, 2012.[14] It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.[15]
Israel: Butylone is a controlled substance.[citation needed]
Norway: Butylone is a controlled substance.[citation needed]
Poland: Butylone is a controlled substance.[citation needed]
Sweden: Butylone is a Schedule I controlled substance as of February 1, 2010.[16]
Switzerland: Butylone is a controlled substance specifically named under Verzeichnis D.[17]
United Kingdom: Butylone is a Class B drug in the United Kingdom as a result of the cathinone catch-all clause.[18]
United States: Butylone is unscheduled in the United States. However it could be considered an analog of methylone or MDMA, thus making it illegal under the scope of the Federal Analog Act.[citation needed]
↑Cozzi, N. V., Sievert, M. K., Shulgin, A. T., Jacob, P., Ruoho, A. E. (17 September 1999). "Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines". European Journal of Pharmacology. 381 (1): 63–69. doi:10.1016/s0014-2999(99)00538-5. ISSN0014-2999.
↑Hofmann, F. G. (1983). A handbook on drug and alcohol abuse: the biomedical aspects (2nd ed ed.). Oxford University Press. ISBN9780195030563.CS1 maint: Extra text (link)
↑Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. eISSN1937-6995. ISSN1556-9039. OCLC163567183.
↑"关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.CS1 maint: Unrecognized language (link)